HMGA2 and leiomyoma: Moreover, the firmly established metabolic differences between leiomyoma types caused by different driver mutations (misfunction of MED12, overproduction of HMGA2, and biallelic inactivation of FH) were not used for the development of specific medicines directed against specific targets of the different nosological forms of uterine leiomyomata except for relatively rare FH-dependent cases.